Protalix (PLX) director awarded restricted shares and long‑dated options
Rhea-AI Filing Summary
Protalix BioTherapeutics (PLX) director Ben Zvi Shmuel received equity awards on 09/03/2025. The filing reports 7,500 restricted shares granted under the companys amended 2006 Stock Incentive Plan, held indirectly by trust to qualify for Israeli Section 102 tax benefits, and 15,000 stock options with a $1.64 exercise price that expire on 09/03/2035. The restricted shares and options each vest in 12 equal quarterly installments commencing on the grant date. The filing also discloses additional outstanding options with various exercise prices and expiration dates.
Positive
- 7,500 restricted shares granted to align director incentives with long‑term shareholder value
- 15,000 stock options with a $1.64 exercise price and 09/03/2035 expiration provide long runway for upside
- Vesting in 12 quarterly installments promotes retention and gradual alignment
- Use of trustee enables eligibility for Israeli Section 102 tax benefits
Negative
- None.
Insights
TL;DR: Director received time‑based equity awards that align incentives without immediate cash impact.
The reported grant of 7,500 restricted shares and 15,000 options vests quarterly over three years, which spreads expense recognition and ties compensation to continued service. The option exercise price of $1.64 and long 2035 expiration create a long runway for potential upside if the stock appreciates. The disclosure of other outstanding options provides context for total potential dilution, but the form does not quantify percentage dilution relative to outstanding shares.
TL;DR: Standard director compensation mechanics and Israeli tax treatment are disclosed; governance appears routine.
Issuing restricted shares through a trustee to satisfy Section 102 tax rules is a common practice for Israeli issuers. Time‑based vesting in 12 quarterly installments is typical for retention-focused grants. The filing is procedural and transparent about grant mechanics and related outstanding option pools, with no indication of special accelerations or departures from customary governance practices.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (Right to Buy) | 15,000 | $0.00 | -- |
| Grant/Award | Common Stock | 7,500 | $0.00 | -- |
Footnotes (1)
- Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the Plan must be registered in the name of a trustee. The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $1.09 per share that expire on June 30, 2032, (ii) options to purchase 10,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 23, 2033.
